ID   WI-L2-729HF2
AC   CVCL_6741
SY   WI-L2-729-HF2; WI-L2-729 HF2; 729-HF2; UC729-HF2; UC729HF2; HF2
DR   CLO; CLO_0009603
DR   ATCC; CRL-8062
DR   Wikidata; Q54994037
RX   Patent=US4594325;
RX   PubMed=3101287;
RX   PubMed=3365703;
RX   PubMed=6350451;
RX   PubMed=6699402;
CC   Group: Hybridoma fusion partner cell line.
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8062.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_9555; Tioguanine (6-thioguanine; 6-TG).
CC   Sequence variation: Mutation; HGNC; HGNC:11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Misspelling: W1-L2-729-HF2; PubMed=3101287.
CC   Discontinued: ATCC; CRL-8062; true.
CC   Derived from site: In situ; Spleen; UBERON=UBERON_0002106.
ST   Source(s): ATCC=CRL-8062
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D5S818: 12,13
ST   D7S820: 9,11
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 17,20
DI   NCIt; C97074; Hereditary spherocytosis
DI   ORDO; Orphanet_822; Hereditary spherocytosis
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D039 ! UC 729-6
SX   Male
AG   5Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 19
//
RX   Patent=US4594325;
RA   Lundak R.L.;
RT   "High fusion frequency fusible lymphoblastoid cell line.";
RL   Patent number US4594325, 10-Jun-1986.
//
RX   PubMed=3101287; DOI=10.1111/j.1423-0410.1986.tb01955.x;
RA   Lowe A.D., Green S.M., Voak D., Gibson T., Lennox E.S.;
RT   "A human-human monoclonal anti-D by direct fusion with a
RT   lymphoblastoid line.";
RL   Vox Sang. 51:212-216(1986).
//
RX   PubMed=3365703;
RA   Kjeldsen T.B., Rasmussen B.B., Rose C., Zeuthen J.;
RT   "Human-human hybridomas and human monoclonal antibodies obtained by
RT   fusion of lymph node lymphocytes from breast cancer patients.";
RL   Cancer Res. 48:3208-3214(1988).
//
RX   PubMed=6350451; DOI=10.4049/jimmunol.131.3.1201;
RA   Abrams P.G., Knost J.A., Clarke G., Wilburn S., Oldham R.K.,
RA   Foon K.A.;
RT   "Determination of the optimal human cell lines for development of
RT   human hybridomas.";
RL   J. Immunol. 131:1201-1204(1983).
//
RX   PubMed=6699402; DOI=10.4049/jimmunol.132.4.1798;
RA   Strike L.E., Devens B.H., Lundak R.L.;
RT   "Production of human-human hybridomas secreting antibody to sheep
RT   erythrocytes after in vitro immunization.";
RL   J. Immunol. 132:1798-1803(1984).
//